On this interview, Information Medical speaks with Dr Bryony Henderson, Medical Director for the UK and US at MedExpress, concerning the evolving position of GLP‑1 agonists in weight problems care and the way forward for metabolic well being remedies.
Please introduce your self and speak just a little about your journey to the place you might be at this time.
I’m the Medical Director for the UK and US at MedExpress, the place I lead our scientific governance and high quality groups. My journey to this position has been outlined by a ardour for secure, progressive, and scalable care.
Earlier than becoming a member of MedExpress, I constructed expertise in scientific operations and digital well being by way of management roles at Kry/Livi and Numan. I’ve all the time been dedicated to being a scientific voice for change, whether or not that’s by way of publishing analysis on well being inequalities or main award-winning public well being campaigns and chatting with nationwide media.
At the moment, my focus is on making certain that as we innovate within the digital area, we stay dedicated to upholding the best requirements of affected person security.
What do GLP-1 agonists do physiologically, and the way ought to sufferers perceive their mechanism of motion?
Physiologically, GLP-1 receptor agonists mimic a naturally occurring hormone that our our bodies produce within the intestine after consuming. These drugs act as a “organic bridge” in three key methods: first, they stimulate the pancreas to launch the correct quantity of insulin; second, they decelerate gastric emptying, that means you are feeling full for longer; and third, maybe most significantly, they work together with the mind’s reward centres to cut back “meals noise” and cravings.
Understanding that it is a hormonal intervention, reasonably than simply an urge for food suppressant, helps sufferers view it as a software to reset their metabolic indicators.
Picture credit score: Alones/Shutterstock.com
Which affected person teams are most definitely to profit from GLP-1-based therapies?
These injections are often prescribed to adults dwelling with weight problems, who’ve a physique mass index (BMI) over 30, or over 27 in the event that they produce other weight-related well being points akin to hypertension or prediabetes.
Nonetheless, trying to 2026, the “profit profile” is increasing, so scientific supervision stays important. Sufferers profit most when remedy is paired with broader way of life restructuring.
Past weight reduction, are there extra well being advantages to utilizing these drugs?
Completely, and this is among the most enjoyable areas of growth for 2026. As scientific proof accumulates, we’re seeing GLP-1s transfer far past the dimensions. We count on to see these drugs prescribed for a broader vary of indications, together with osteoarthritis, heart problems, and continual kidney illness. By 2026, we might also see their software in treating sleep apnoea and even sure neurodegenerative circumstances. We’re shifting from “weight reduction medicine” to “metabolic well being stabilisers.”
How sustainable are the outcomes when sufferers stay on remedies, and after they stop therapy?
Sustainability is extremely depending on the “wraparound” care supplied. GLP-1s are extremely efficient at inducing weight reduction, whereas on the therapy, we all know that weight problems is a continual situation. And not using a strong transition plan, starvation indicators can return if therapy is ceased.
For this reason, at MedExpress, we concentrate on elevated personalization; by 2026, I count on to see extra subtle dosing schedules and monitoring instruments that assist sufferers keep their “non-scale” well being enhancements long-term, whether or not they stay on a upkeep dose or transition off it.
How do you handle affected person expectations, notably notion of GLP-1 agonists as a “fast repair”, and may psychological assist be thought of with these drugs?
Managing the “fast repair” narrative is a core a part of scientific governance. We should be clear: these are medical interventions, not “vainness medicine”. Psychological assist will not be an elective further; it’s typically important. We have to deal with the behavioral relationship with meals concurrently.
For my part, probably the most profitable therapy fashions in 2026 will likely be people who mix remedy with behavioral change to make sure the affected person’s way of life evolves alongside their biology.
What challenges do you see round entry, affordability, and fairness in prescribing GLP-1 agonists? Are there variations in private-prescribing fashions in comparison with NHS and public well being approaches to weight problems care?
Picture credit score: IM Imagery/Shutterstock.com
It is a essential situation. Entry by way of techniques just like the NHS stays restricted in comparison with scientific want. The NHS is exploring new rollout fashions, however uptake nonetheless solely represents a fraction of the eligible inhabitants. This creates a “two-tier” system wherein non-public prescribing presents earlier entry.
Nonetheless, 2026 will likely be a turning level: as semaglutide loses patent safety in main world markets, akin to China, Canada, and Brazil, and with liraglutide already off-patent within the US, the expansion of generics is anticipated to drive down prices and enhance world fairness.
Do you suppose present pointers and approvals strike the best stability between widening entry to GLP-1 agonists and making certain applicable scientific oversight, and what adjustments, if any, would you make?
The present pointers provide a robust security framework, however there’s room for additional growth. As we transfer towards 2026, I want to see pointers that enable for extra “dosing flexibility” and personalised therapy paths. We have to be sure that widening entry, a public well being necessity, doesn’t come on the expense of scientific oversight.
My focus is on making certain that, whatever the supply mannequin, the affected person is all the time underneath the care of a clinician who screens metrics akin to blood strain and coronary heart fee variability.
Do you suppose GLP-1 agonists are altering how weight problems is perceived, as a medical situation versus way of life decisions?
Sure, we’re witnessing a profound shift. They’re serving to dismantle the “willpower fantasy.” By demonstrating how hormonal pathways affect weight, these remedies are reframing weight problems as a continual metabolic illness reasonably than a life-style selection. This shift in notion is significant for lowering the stigma that has prevented many sufferers from looking for assist up to now.
How do you see GLP-1 agonists becoming into long-term, holistic weight problems care over the following decade?
Over the following decade, GLP-1s would be the “anchor” of a way more holistic, data-driven method. We’ll see an growth of choices, together with new mixture therapies and oral formulations like orforglipron, which can provide sufferers extra selection in how they take their remedy. We’ll see expanded choices together with mixture therapies and oral formulations like orforglipron, integrating remedy with wearable tech, actual‑time metabolic monitoring, and tailor-made dietary teaching. We’re shifting away from a “one-size-fits-all” and in direction of personalised lifelong metabolic well being administration.
The place can readers discover extra data?
In regards to the Researcher
Dr. Bryony Henderson joins HeliosX as Medical Director for the UK and US, bringing in depth expertise in scientific operations, governance and digital well being from her roles at Kry/Livi and Numan. A recognised scientific voice, she has contributed to award-winning campaigns, printed on well being inequalities, and appeared throughout main nationwide media. At HeliosX, she leads scientific governance and high quality, supporting the supply of secure, progressive, and scalable care.